MiMedx Highlights Skills and Experience of Director Nominees
Time is short. The Annual Meeting is scheduled for
The Company's nominees –
In contrast, the hand-picked nominees put forth by the Company's former Chairman and CEO, Parker H. ("Pete") Petit, include a former tax advisor for a home builder and a
All leading independent proxy advisory firms – Institutional Shareholder Services ("ISS"),
Institutional investors such as mutual, pension and retirement funds rely on the recommendations from proxy advisory firms ISS,
Meet
Proposed Chairwoman
Dr. Behrens Wilsey has experience in:
- Managing healthcare and life sciences companies. Dr. Behrens Wilsey is as an independent life sciences consultant and investor and served as Co-Founder, President and CEO as well as a director of the
KEW Group Inc. , a private oncology services company. - Public company board service. She is Chairwoman of
Sarepta Therapeutics, Inc. , an$8.7 billion market cap company, and previously served on the boards ofAmylin Pharmaceuticals, Inc. until it was acquired byBristol-Myers Squibb Co. andAbgenix, Inc. until it was acquired byAmgen, Inc. - Investing and finance. She served as a general partner for selected venture funds for RS Investments, a mutual fund firm, and as a general partner and managing director for
Robertson Stephens & Co. , an investment company. - If elected, Dr. Behrens Wilsey is expected to become the Chairwoman of the Board.
K. Todd Newton
Proposed Audit Chair
Mr. Newton has experience in:
- Finance and accounting. In addition to serving as CFO at
ArthroCare Corporation , Mr. Newton was also a Partner atDeloitte & Touche LLP . - C-suite leadership. Mr. Newton is the CEO of
Apollo Endosurgery, Inc. , a medical device company. He previously served as Executive Vice President, Chief Financial Officer and Chief Operating Officer atArthroCare Corporation . He also served as President and CEO atSynenco Energy, Inc. , a Canadian oil sands company. - Public company board service. Mr. Newton is currently a director on
Apollo Endosurgery, Inc.'s board and was previously a director atSynenco Energy, Inc. - If elected, Mr. Newton is expected to become the Audit Committee Chairman after the 2019 Annual Meeting.
Chief Executive Officer
Mr. Wright has experience in:
- Pharmaceutical, biotech and medical device industries. Mr. Wright currently serves as Chief Executive Officer of
MiMedx . Previously, he served as Chief Executive Officer atM2Gen Corp. ,Curaxis Pharmaceutical Corporation and AAI Pharma. - Business development and expansion. Mr. Wright has a strong track record of revenue growth and margin expansion, notably from his experience as Executive Vice President, Head of M&A, Strategy and Innovation at
Teva Pharmaceutical Industries Ltd. He has served as President of Imaging Solutions and Pharmaceuticals Products for Covidien PLC and was the founding partner ofThe Ohio State University's Comprehensive Cancer Drug Development Institute . He was also Head of Marketing forDuPont Merck Pharmaceutical Co. , where he progressed to several executive roles outsidethe United States . - Board experience. He was the lead independent director of
Agenus, Inc. and a board member ofCuraxis Pharmaceutical Corporation . He currently serves as Chairperson ofThe Ohio State University Comprehensive Cancer Center Drug Development Institute and serves as director ofThe Ohio State Innovation Foundation .
Mr. Petit's Nominees Lack the Experience Needed to Rebuild MiMedx
MIMEDX NOMINEES |
PETE PETIT'S NOMINEES |
|||||
Dr. M. Kathleen Behrens Wilsey |
K. Todd Newton |
Timothy R. Wright |
Pete Petit |
David Furstenburg |
Shawn George |
|
• |
• |
• |
New to MiMedx |
• |
• |
|
• |
• |
• |
Public company board experience |
• |
||
• |
• |
• |
Healthcare experience |
• |
||
• |
• |
• |
Unblemished public company record |
NO RECORD |
NO RECORD |
Materials about the upcoming meeting, including the Company's definitive proxy statement, can be accessed at www.VoteBlueForMiMedx.com.
Your Vote Is Important, No Matter How Many or How Few Shares You Own.
If you have questions about how to vote your shares, or need additional assistance, please contact the firm assisting
INNISFREE M&A INCORPORATED
Shareholders may call toll-free at 1 (877) 800-5195
Banks and Brokers may call 1 (212) 750-5833
If you have already done so, you can change your vote by using the BLUE proxy card to vote TODAY—by telephone, by Internet or by signing, dating and returning the BLUE proxy card in the postage-paid envelope provided.
About
MiMedx® is an industry leader in advanced wound care and an emerging therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization.
Forward-Looking Statements
This press release includes forward-looking statements, including statements regarding the future composition of the Board and expectations with respect to Board leadership. Forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," "would" and similar expressions and are based on current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements.
Actual results may differ materially from those set forth in the forward-looking statements as a result of various factors, including the results of any election at the 2018 Annual Meeting or the Company's 2019 annual meeting of shareholders (the "2019 Annual Meeting"). There is no assurance that the Company's nominees will be elected at the 2018 Annual Meeting or the 2019 Annual Meeting. Any forward-looking statements speak only as of the date of this press release, and except as required by law, the Company assumes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contacts
Investors:
Corporate & Investor Communications
770.651.9066
investorrelations@mimedx.com
Media:
212.355.4449
View original content to download multimedia:http://www.prnewswire.com/news-releases/mimedx-highlights-skills-and-experience-of-director-nominees-300867113.html
SOURCE